Terapia Génica del Cáncer
TGC
![Foto de Terapia Génica del Cáncer](/img/uploaded/2638e8f8b318fa3e2dc194b3248c709e.jpg)
![Foto de University College London](/img/noimage_org.png)
University College London
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de University College London (21)
2024
-
Fcγ receptors and immunomodulatory antibodies in cancer
Nature Reviews Cancer, Vol. 24, Núm. 1, pp. 51-71
-
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma
Nature Cancer
2023
-
Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Nature, Vol. 616, Núm. 7957, pp. 563-573
-
Body composition and lung cancer-associated cachexia in TRACERx
Nature Medicine, Vol. 29, Núm. 4, pp. 846-858
-
Evolutionary characterization of lung adenocarcinoma morphology in TRACERx
Nature Medicine
-
Genomic–transcriptomic evolution in lung cancer and metastasis
Nature, Vol. 616, Núm. 7957, pp. 543-552
-
Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials
The oncologist, Vol. 28, Núm. 4, pp. e205-e211
-
Lung adenocarcinoma promotion by air pollutants
Nature, Vol. 616, Núm. 7955, pp. 159-167
-
Protective ileostomy creation after anterior resection of the rectum: Shared decision-making or still subjective?
Colorectal Disease, Vol. 25, Núm. 4, pp. 647-659
-
The evolution of lung cancer and impact of subclonal selection in TRACERx
Nature, Vol. 616, Núm. 7957, pp. 525-533
-
The evolution of non-small cell lung cancer metastases in TRACERx
Nature, Vol. 616, Núm. 7957, pp. 534-542
-
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Nature, Vol. 616, Núm. 7957, pp. 553-562
2022
-
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
Nature Cancer, Vol. 3, Núm. 6, pp. 696-709
-
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
Nature Cancer, Vol. 3, Núm. 11, pp. 1336-1350
-
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling (Nature Cancer, (2022), 3, 11, (1336-1350), 10.1038/s43018-022-00447-1)
Nature Cancer
-
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery
BJS Open, Vol. 6, Núm. 1
2020
-
Atypical patterns of response and progression in the era of immunotherapy combinations
Future Oncology, Vol. 16, Núm. 23, pp. 1707-1713
-
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
Annals of Oncology, Vol. 31, Núm. 10, pp. 1405-1412
2018
-
Intratumoral immunotherapy with XCL1 and sFlt3L encoded in recombinant semliki forest virus–derived vectors fosters dendritic cell–mediated t-cell cross-priming
Cancer Research, Vol. 78, Núm. 23, pp. 6643-6654